Porcine circovirus and parvovirus vaccine
The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.
1. A vaccine for eliciting a protective response against porcine circovirus type II infection comprising at least one porcine parvovirus antigen and at least one inactivated porcine circovirus type II, and a veterinarily acceptable vehicle or excipient.
2. The vaccine of claim 1 , wherein the porcine parvovirus antigen is selected from the group consisting of an attenuated porcine parvovirus, an inactivated porcine parvovirus, a subunit of porcine parvovirus, and a vector that contains and expresses in vivo a nucleic acid molecule encoding the porcine parvovirus antigen.
3. The vaccine of claim 1 , wherein the porcine circovirus type II is at least one porcine circovirus type II deposited at the ECACC selected from group consisting of: porcine circovirus type II accession No. V97100219, porcine circovirus type II accession No. V97100218, porcine circovirus type II accession No. V97100217, porcine circovirus type II accession No. V98011608, and porcine circovirus type II accession No. V98011609.
4. The vaccine of claim 1 , wherein the vaccine further comprises an additional antigen of another porcine pathogen.
5. The vaccine of claim 4 , wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of Mycoplasma hypopneumoniae, an antigen of Actinobacillus pleuropneumoniae, an antigen of E. coli, an antigen of Atrophic Rhinitis, an antigen of Pseudorabies virus, an antigen or Hog cholera, an antigen of Swine Influenza, and combinations thereof.
6. The vaccine of claim 4 , wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.
7. A composition for eliciting a protective immunological response against porcine parvovirus and an immunological response against porcine circovirus comprising at least one porcine parvovirus antigen and at least one porcine circovirus antigen, and a veterinarily acceptable vehicle or excipient.
8. The composition of claim 7 wherein the porcine parvovirus antigen is selected from the group consisting of an attenuated porcine parvovirus, an inactivated porcine parvovirus, a subunit of porcine parvovirus, and a vector that contains and expresses in vivo a nucleic acid molecule encoding the porcine parvovirus antigen; and the porcine circovirus antigen is selected from the group consisting of an attenuated porcine circovirus, an inactivated porcine circovirus, a subunit of porcine circovirus, and a vector that contains and expresses in vivo a nucleic acid molecule encoding the porcine circovirus antigen.
9. The composition of claim 7 wherein the composition further comprises an additional antigen of another porcine pathogen.
10. The composition of claim 9 wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of Mycoplasma hypopneumoniae, an antigen of Actinobacillus pleuropneumoniae, an antigen of E. coli, an antigen of Atrophic Rhinitis, an antigen of Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.
11. The composition of claim 9 wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.
12. The composition according to claim 7 wherein the antigen or porcine circovirus comprises antigens of a plurality of porcine circoviruses.
13. A method for inoculating against porcine parvovirus and porcine circovirus comprising administering to a porcine the composition as claimed in claim 7 .
14. A kit for preparing the composition of claim 7 comprising (i) the at least one porcine parvovirus antigen and (ii) the at least one porcine circovirus antigen, wherein (i) and (ii) are packaged separately.
15. The kit of claim 14 wherein the porcine circovirus antigen comprises at least one porcine circovirus type II antigen.
16. The composition of claim 7 wherein the porcine circovirus antigen comprises at least one porcine circovirus type II antigen.
17. The composition of claim 16 wherein the porcine circovirus type II antigen is at least one antigen of a porcine circovirus type II deposited at the ECACC selected from group consisting of: porcine circovirus type II accession No. V97100219, porcine circovirus type II accession No. V97100218, porcine circovirus type II accession No. V97100217, porcine circovirus type II accession No. V98011608, and porcine circovirus type II accession No. V98011609.
18. The composition of claim 16 wherein the porcine circovirus type II antigen is an attenuated virus porcine circovirus type II.
19. The composition of claim 18 further comprising a veterinarily acceptable adjuvant.
20. The composition of claim 18 further comprising a freeze-drying stabilizer.
21. The composition of claim 16 wherein the porcine circovirus type II antigen is an inactivated porcine circovirus type II.
22. The composition of claim 21 further comprising a veterinarily acceptable adjuvant.
23. The composition of claim 16 wherein the composition further comprises an additional antigen of another porcine pathogen.
24. The composition of claim 23 wherein the additional antigen of another porcine pathogen is selected from the group consisting of: an antigen of PRRS virus, an antigen of Mycoplasma hypopneumoniae, an antigen of Actinobacillus pleuropneumoniae, an antigen of E. coli, an antigen of Atrophic Rhinitis, an antigen of Pseudorabies virus, an antigen of Hog cholera, an antigen of Swine Influenza, and combinations thereof.
25. The composition of claim 24 wherein the additional antigen of another porcine pathogen is an antigen of PRRS virus.